T1	Participants 803 980	32 patients (18 ursodeoxycholic acid, 14 placebo) indicated that at 2 yr, ursodeoxycholic acid comprised 65% of serum bile acids in the treated group and 7% in the placebo group
T2	Participants 235 274	patients with primary biliary cirrhosis
